SCHEMBL3756784

SCHEMBL3756784

CCOC(=O)CNC(=O)c1c(O)ccc2ncc(-c3ccccc3)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
EGLN3 Q9H6Z9 1/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 6/20 0.42
LMNA P02545 2/20 0.42
CASP1 P29466 1/20 0.41
FTO Q9C0B1 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
CCR6 P51684 1/20 0.41
PPID Q08752 1/20 0.40
ABL1 P00519 1/20 0.39
P2RY12 Q9H244 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518478 0.92 EGLN3 (0.50) NPC1RAB9AEGLN3HPGDHSD17B10
SCHEMBL3520840 0.86 EGLN3 (0.63) EGLN3ALDH1A1LMNAFTOEGLN1
SCHEMBL3761570 0.85 EGLN3 (0.45) NPC1RAB9AEGLN3HPGDHSD17B10
SCHEMBL3524259 0.85 EGLN3 (0.52) NPC1RAB9AEGLN3HPGDHSD17B10
SCHEMBL3761475 0.84 NPC1 (0.45) NPC1RAB9AEGLN3HPGDHSD17B10
SCHEMBL3517992 0.84 ALDH1A1 (0.49) EGLN3HPGDHSD17B10ALDH1A1LMNA
SCHEMBL3759035 0.83 CASP1 (0.40) NPC1RAB9AEGLN3HPGDHSD17B10
SCHEMBL3521384 0.83 CASP1 (0.49) NPC1RAB9AEGLN3HPGDHSD17B10
SCHEMBL3521148 0.83 EGLN3 (0.46) NPC1RAB9AEGLN3HPGDHSD17B10
SCHEMBL3761359 0.82 MAPK1 (0.45) NPC1RAB9AEGLN3HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 NPC1 2674/4885RAB9A 3111/4885EGLN3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.